Johnson & Johnson (JNJ)

For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.

Rising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru.

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.

President Trump unveils a $600 billion Saudi investment package into the U.S., with major deals in tech, defense, energy, and healthcare.

It's biggest product will be up for price negotiations under the Inflation Reduction Act much sooner than expected.

Stay updated with the S&P500 stocks that are on the move in today's pre-market session.

It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.

Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk's stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main culprits, not Big Pharma.

Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.

What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription drug prices.

Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%.

Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.

The company said that 66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational oral Icotrokinra achieved site-specific clear or almost clear skin at week 16.

Before Kenvue and Johnson & Johnson, Ruh was at PepsiCo for 17 years.

Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.

Marjorie Taylor Greene disclosed buying more than 50 stocks in early May. A look at the list and why the congresswoman's past trades have drawn red flags.

FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.

President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new tariffs on imported medicines within two weeks

FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases.

Trump claims he might personally phone CEOs for business moves he dislikes, using this tactic on Amazon's Bezos over tariff disclosures.